Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well...

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round New specialist European and US life sciences investors join existing investors to enable Nouscom to continue advancing the clinical development of its portfolio of neoantigen cancer vaccines to key...

Nouscom’s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to ‘Intercept’ Cancer in Subjects with Lynch Syndrome Lynch Syndrome is a common hereditary condition associated with a genetic predisposition to and high-risk of developing colorectal and other cancersPhase 1b trial evaluating NOUS-209 monotherapy in...

Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023 NOUS-PEV demonstrated good safety and immunogenicity, and induced durable neoantigen-specific T cell responses that were detected for over 6 months and increased T cell infiltration in tumors...

Nouscom Announces AACR 2023 Late-Breaking Presentation of Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy BASEL, Switzerland – 15th March 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector immunotherapies, today announced that new translational...